Share this article
Share this article
LIEGE, Belgium, June 3, 2021 /PRNewswire/ Amyl Therapeutics ( Amyl ), a preclinical stage biotechnology company developing its amyloid fibrils specific
technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18.3 million Series A financing. The funding round comprises €8.6 million in equity led by Noshaq - a regional Belgian private-public fund - with support from Merieux Participations, Sambrinvest and other private investors; and €9.7 million in non-dilutive funding from the DG06 – a key policy-design and implementing body for research and innovation policy in the Walloon region of Belgium.
姑苏区北部经济区建设首家人才公寓_中国江苏网
jschina.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jschina.com.cn Daily Mail and Mail on Sunday newspapers.
Alibaba Business School Kicks Off Third Netpreneur Training Initiative for
newswit.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswit.com Daily Mail and Mail on Sunday newspapers.
ESCAPE Bio Appoints Edward Owens and Scott Morrison to Board of Directors SOUTH SAN FRANCISCO, Calif. (Business Wire) ESCAPE Bio Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, announced that Edward Owens and Scott Morrison have been appointed to the Board of Directors.
“Ed brings an unparalleled perspective of our industry based on over four decades of outstanding performance investing in healthcare companies,” said Julie Anne Smith, CEO. “We are delighted to have his insight on business fundamentals, industry insights and shareholder value.”
“Scott is a well-respected industry leader who brings over 40 years of financial experience helping life science companies grow from start-up, through initial product launch, to global expansion,” said Tony Rimac, CFO. “We look forward to his financial acumen and corporate insight as we advance our pipeline of Precision Neurology medicines.”